With insulin pump therapy provided during hospitalization it is possible to standardize the sugar control profile in patients with type 2 diabetes mellitus in a short period of time, thereby allowing for the further evaluation of the clinical response to GLP-1 analogues. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.